Breast cancer accounts for 29% of malignant tumors. It is an heterogenous disease covering a spectrum of different molecular subtypes. Epigenetic aberrations may affect gene expression through DNA and histone proteins modifications thus promoting tumor progression and resistance to anti- tumor treatment. ...
Combination of HDAC inhibitor and anti-PD-L1 antibody for treatment of cancer Described herein are methods for the treatment of breast cancer in a subject. In particular, methods are provided for the treatment of metastatic triple negative breast cancer with a combination of entinostat and an anti...
Entinostat has been widely investigated for the treatment of cancer, in which results have shown the in vitro anti-proliferative activity of entinostat in a wide range of human cancer cell lines, including breast, colon, lung, myeloma, ovary, pancreas, prostate and leukemia. Reference Hess-Stumpp...
Entinostat has been widely investigated for the treatment of cancer, in which results have shown the in vitro anti-proliferative activity of entinostat in a wide range of human cancer cell lines, including breast, colon, lung, myeloma, ovary, pancreas, prostate and leukemia. Reference Hess-Stumpp...
CT screenings to see if the cancer returns, there have been no additional treatment options for ...
with exemestane for the treatment of hormone therapy refractory breast cancer. Based on results from the phase II ENCORE 301 study, entinostat showed potential to reverse resistance to hormonal therapies in patients, with advancedER+breast cancer[110]. This has prompted its evaluation in the phase ...
Advancing Melanoma Treatment: Hamid on Lifileucel's Role Jordyn Sava;Omid Hamid, MD July 15th 2024 Podcast In this episode of Targeted Talks, Omid Hamid, MD, discusses data supporting the use of lifileucel for the treatment of advanced melanoma. ...
Bars, S.D. The data are representative of three independent experiments paclitaxel.57 Thus, novel strategies or agents simultaneously targeting both erbB2 and erbB3 may have a broader impact on treatment of breast cancer. Here, we propose a novel approach to target erbB2/erbB3—reducing their ...
Moreover, safety and tolerability of the combination given either in neoadjuvant or metastatic setting will be evaluated. Response is defined as ≥ 50% reduction in Ki67 AND ≥ 1% ER-positivity OR pathologic complete response in the post-treatment surgical specimens.Statistical Methods: For the ...
Classic Hodgkin lymphoma (HL) is one of the most curable human cancers. However, treatment of patients with relapsed and refractory disease, especially those who relapse after autologous stem cell transplantation, remains challenging: the median survival for these patients is typically fewer than 3 ye...